Leveraging The Right RNA Polymerase To Reduce Immunogenicity And Enhance Capping Efficiency

Advancements in RNA biology have opened up new possibilities for using mRNA as a therapeutic approach. mRNA-based vaccines have proven effective in targeting previously untreatable molecular targets and offer advantages over DNA-based vectors in terms of safety and adaptability. The field of mRNA therapeutics has garnered significant attention and investment, resulting in breakthroughs in understanding the structure and immune response of mRNA therapeutics.

One promising development in the production of RNA therapeutics is the use of in vitro transcription (IVT) from DNA templates. By utilizing Codex HiCap RNA Polymerase, researchers have found a way to reduce the production of double-stranded RNA byproducts, which can contribute to immunogenicity. This optimization strategy has the potential to enhance the functionality and safety of mRNA therapeutics. This exciting progress in mRNA therapeutics holds great promise for the treatment of a wide range of diseases.

As our understanding of mRNA biology continues to grow, we can expect further advancements in the development and optimization of mRNA-based therapies. Learn how leveraging an engineered co-transcriptional capping RNA Polymerase can optimize the safety and effectiveness of mRNA therapeutics.